Search results
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 5 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,
Digestive Disease Week 2024 - Nature Reviews Gastroenterology & Hepatology
Nature· 6 days agoFrom 18–21 May 2024, Nature Reviews Gastroenterology & Hepatology was back at Digestive Disease Week (DDW) in Washington DC, USA, alongside >14,300 attendees both in person and virtually, according ...
Advice | What the latest science says about Lyme disease
Washington Post· 6 days agoLyme disease is a bacterial infection that spreads through tick bites. It may cause flu-like symptoms and a bull’s-eye-shaped rash. Most people fully recover after a few weeks of antibiotic ...